Breaking News Instant updates and real-time market news.

VSAR

Versartis

$1.21

0.025 (2.12%)

, ARAV

Aravive

$0.00

(0.00%)

07:04
10/15/18
10/15
07:04
10/15/18
07:04

Versartis, Aravive Biologics complete merger

Aravive Biologics, Inc. and Versartis, Inc. (VSAR) announced that the merger of the two companies has closed following Versartis stockholder approval on October 5, 2018. Beginning tomorrow, October 16, 2018, the combined company will operate as Aravive, Inc. and its shares will trade on the Nasdaq Global Select Market under the new ticker symbol "ARAV". Aravive, Inc. is a clinical stage biotechnology company focusing on developing innovative therapies that target important survival pathways for cancer.Concurrent with the close of the merger, the combined company, Aravive, Inc., announced a 1-for-6 reverse split of its common shares. The reverse split will be effective upon opening of trading tomorrow, October 16, 2018. When the reverse split becomes effective, every 6 shares of issued and outstanding "ARAV" common stock will be combined into 1 issued and outstanding share of common stock with no changes to the par value of the shares. The reverse split will reduce the number of shares of Aravive's outstanding common stock from approximately 67.1 million to approximately 11.2 million. Unaudited pro forma cash and cash equivalents for the combined company as of the close of the merger is expected to be in the range of $60.0 million to $62.0 million, net of all estimated transaction costs. Following the completion of the merger, the board of directors of the combined company will include Srinivas Akkaraju, M.D., Ph.D., chairman; Jay Shepard, president and chief executive officer; Shahzad Malik, M.D; Amato Giaccia, Ph.D., scientific founder of Aravive Biologics; Ray Tabibiazar, M.D., founder and former executive chairman of Aravive Biologics; and Eric Zhang, CFA. In addition, concurrent with the close of the merger, the board of directors has appointed an additional independent director, Robert E. Hoffman. Hoffman is currently CFO and senior vice president, finance of Heron Therapeutics (HRTX).

VSAR

Versartis

$1.21

0.025 (2.12%)

ARAV

Aravive

$0.00

(0.00%)

HRTX

Heron Therapeutics

$29.40

0.39 (1.34%)

VSAR Versartis
$1.21

0.025 (2.12%)

09/18/18
JPMS
09/18/18
NO CHANGE
Target $81
JPMS
Overweight
Market evolving favorably for Ascendis into Phase III results, says JPMorgan
JPMorgan analyst Jessica Fye believes the long-acting growth hormone deficiency competitive landscape is evolving favorably for Ascendis Pharma heading into the Phase III results for the company's TransCon growth hormone in Q1 of 2019. The past 12-24 months has brought emerging clinical issues for all three of the key long-acting competitors, Fye tells investors in a research note. These range from the failure of Versartis (VSAR) at the most extreme, to the missed pivotal trial in adults for Pfizer (PFE) and Opko (OPK), to results that may raise questions around efficacy for Novo (NVO) in adults, Fye contends. The analyst believes these create opportunity for Ascendis, assuming the company is successful in Phase III. She continues to have high conviction in the success of the Phase III trial and keeps an Overweight rating on Ascendis Pharma with an $81 price target.
03/02/18
ADAM
03/02/18
DOWNGRADE
Target $5
ADAM
Hold
Versartis downgraded to Hold with $5 price target at Canaccord
As reported previously, Canaccord analyst John Newman downgraded Versartis to Hold from Buy as the company explores strategic alternatives, which he believes includes a sale of the company. Due to the uncertainty of the strategic process, he prefers to move to the sidelines. Newman lowered his price target to $5 from $9 on Versartis shares.
03/02/18
ADAM
03/02/18
DOWNGRADE
ADAM
Hold
Versartis downgraded to Hold from Buy at Canaccord
ARAV Aravive
$0.00

(0.00%)

HRTX Heron Therapeutics
$29.40

0.39 (1.34%)

10/02/18
ADAM
10/02/18
NO CHANGE
Target $49
ADAM
Hold
Pacira price target raised to $49 from $45 at Canaccord
Canaccord analyst Dewey Steadman maintained a Hold rating on Pacira Pharmaceuticals (PCRX) and raised his price target to $49 from $45. Recently reported IQVIA monthly data for August show a major acceleration of volume and revenue growth vs. a year ago as well as substantial alignment in growth trends with Symphony Health data, Steadman tells investors in a research note. Longer term, however, he remains concerned about the potential advent of competition from Heron's (HRTX) HTX-011 with what some consider to be a superior clinical data set to Exparel, and expects Pacira shares could be rangebound for the near future following strong recent performance.
09/21/18
CANT
09/21/18
NO CHANGE
Target $50
CANT
Overweight
Heron Therapeutics selloff not based on fundamentals, says Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes sees no fundamental reason for the recent weakness in shares of Heron Therapeutics. The pullback provides a "compelling entry point," Folkes tells investors in a research note. He believes the market opportunity for HTX-011 "remains compelling," with peak sales potential of over $1B. The analyst reiterates an Overweight rating on Heron with a $50 price target.
09/13/18
STFL
09/13/18
INITIATION
Target $55
STFL
Buy
Heron Therapeutics initiated with a Buy at Stifel
Stifel analyst Derek Archila initiated Heron Therapeutics with a Buy rating and a price target of $55. The analyst expects the company's HTX-011 to be approved for the prevention of postsurgical pain, becoming "the first product to receive an opioid sparing indication from the FDA". Archila adds that shares could be driven higher amid the "continued discussion about potential legislation to unbundle branded non-opioid analgesic".
09/13/18
STFL
09/13/18
INITIATION
Target $41
STFL
Sell
Pacira initiated with a Sell at Stifel
Stifel analyst Derek Archila initiated Pacira (PCRX) with a Sell rating and a price target of $41, saying the stock price is not "particularly cheap" following the rally driven by an upward revision to Exparel sales guidance during its Q2 earnings call. The analyst adds that the approval of Heron's (HRTX) HTX-011 also creates a "medium- to long-term headwind" for Pacira.

TODAY'S FREE FLY STORIES

01:50
11/19/19
11/19
01:50
11/19/19
01:50
General news
Asian Market Update: »

Asian Market Update:…

EFC

Ellington Financial

$18.79

0.01 (0.05%)

20:29
11/18/19
11/18
20:29
11/18/19
20:29
Syndicate
Ellington Financial 4.2M share Spot Secondary priced at $18.20 »

The stock priced below…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

HD

Home Depot

$238.98

1.64 (0.69%)

, MDT

Medtronic

$111.25

-0.86 (-0.77%)

20:25
11/18/19
11/18
20:25
11/18/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

HD

Home Depot

$238.98

1.64 (0.69%)

MDT

Medtronic

$111.25

-0.86 (-0.77%)

TJX

TJX

$59.54

-0.25 (-0.42%)

TDG

TransDigm

$568.32

9.81 (1.76%)

ARMK

Aramark

$43.90

0.25 (0.57%)

KSS

Kohl's

$58.39

-0.71 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 05

    Dec

  • 11

    Dec

ACY

AeroCentury

$3.31

-0.66 (-16.62%)

20:01
11/18/19
11/18
20:01
11/18/19
20:01
Hot Stocks
AeroCentury sells one Bombardier CRJ900 to Aeronautical Support International »

AeroCentury announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$6.02

-0.14 (-2.27%)

19:29
11/18/19
11/18
19:29
11/18/19
19:29
Hot Stocks
Myovant Sciences up over 11% after announcing Phase 3 Study conference call »

Shares of Myovant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$29.95

-0.04 (-0.13%)

18:47
11/18/19
11/18
18:47
11/18/19
18:47
Hot Stocks
Invitation Homes CEO sells 70K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$369.50

-2.05 (-0.55%)

, LUV

Southwest

$57.77

-0.03 (-0.05%)

18:44
11/18/19
11/18
18:44
11/18/19
18:44
Periodicals
Boeing to provide Southwest board with 737 MAX update this week, Reuters says »

Boeing (BA) this week…

BA

Boeing

$369.50

-2.05 (-0.55%)

LUV

Southwest

$57.77

-0.03 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 23

    Jan

GBDC

Golub Capital

$17.79

0.045 (0.25%)

18:42
11/18/19
11/18
18:42
11/18/19
18:42
Upgrade
Golub Capital rating change at Keefe Bruyette »

Golub Capital upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

GM

General Motors

$36.62

-0.25 (-0.68%)

, TM

Toyota

$143.53

-0.76 (-0.53%)

18:42
11/18/19
11/18
18:42
11/18/19
18:42
Periodicals
CA to halt purchase of GM, Toyota, Fiat Chrysler vehicles, Reuters reports »

The state of California…

GM

General Motors

$36.62

-0.25 (-0.68%)

TM

Toyota

$143.53

-0.76 (-0.53%)

FCAU

Fiat Chrysler

$15.63

-0.39 (-2.43%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

CRMT

America's Car-Mart

$90.88

3.22 (3.67%)

, WUBA

58.com

$50.26

-1.35 (-2.62%)

18:38
11/18/19
11/18
18:38
11/18/19
18:38
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

CRMT

America's Car-Mart

$90.88

3.22 (3.67%)

WUBA

58.com

$50.26

-1.35 (-2.62%)

BILI

Bilibili

$16.39

-0.32 (-1.92%)

SAEX

SAExploration

$1.51

-0.05 (-3.21%)

CLVS

Clovis

$7.05

0.68 (10.68%)

NOW

ServiceNow

$266.56

6.65 (2.56%)

OKTA

Okta

$121.21

3.76 (3.20%)

SPLK

Splunk

$122.64

3.49 (2.93%)

WWD

Woodward

$113.64

-1.15 (-1.00%)

KRNT

Kornit Digital

$33.07

-1.13 (-3.30%)

ASH

Ashland

$78.65

0.03 (0.04%)

VNET

21Vianet

$8.28

0.23 (2.86%)

DHT

DHT Holdings

$7.52

-0.2 (-2.59%)

KRTX

Karuna Therapeutics

$94.70

77.44 (448.67%)

EGHT

8x8, Inc.

$20.78

0.13 (0.63%)

I

Intelsat

$7.98

-5.42 (-40.45%)

PFGC

Performance Food Group

$46.09

-0.08 (-0.17%)

EFC

Ellington Financial

$18.79

0.01 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 16

    Dec

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

LEVI

Levi Strauss

$17.06

-0.115 (-0.67%)

18:31
11/18/19
11/18
18:31
11/18/19
18:31
Hot Stocks
Levi Strauss CEO: I believe in the importance of innovation »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$45.17

0.07 (0.16%)

18:17
11/18/19
11/18
18:17
11/18/19
18:17
Periodicals
Cisco sues former employees over claims of trade secret theft, Bloomberg says »

Cisco is suing two…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 12

    Feb

ABBV

AbbVie

$88.71

0.07 (0.08%)

18:09
11/18/19
11/18
18:09
11/18/19
18:09
Hot Stocks
AbbVie treatment of myelofibrosis granted FDA orphan status »

AbbVie's navitoclax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

PRQR

ProQR Therapeutics

$6.27

-0.64 (-9.26%)

18:06
11/18/19
11/18
18:06
11/18/19
18:06
Hot Stocks
ProQR Therapeutics treatment of retinal dystrophy in P23H granted orphan status »

ProQR Therapeutics'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BILI

Bilibili

$16.39

-0.32 (-1.92%)

18:04
11/18/19
11/18
18:04
11/18/19
18:04
Earnings
Bilibili sees Q4 revenue RMB1.93B-RMB1.98B »

Q4 revenue consensus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

WUBA

58.com

$50.26

-1.35 (-2.62%)

18:03
11/18/19
11/18
18:03
11/18/19
18:03
Earnings
58.com sees Q4 revenue up 12%-15% in RMB terms »

Based on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BILI

Bilibili

$16.39

-0.32 (-1.92%)

18:03
11/18/19
11/18
18:03
11/18/19
18:03
Hot Stocks
Bilibili reports average MAUs reached 127.9M in Q3 »

Average monthly active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

WUBA

58.com

$50.26

-1.35 (-2.62%)

18:03
11/18/19
11/18
18:03
11/18/19
18:03
Earnings
58.com reports Q3 adjusted EPS 96c, consensus 82c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BILI

Bilibili

$16.39

-0.32 (-1.92%)

18:01
11/18/19
11/18
18:01
11/18/19
18:01
Earnings
Bilibili reports Q3 adjusted EPS (15c), consensus (14c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

DDOG

Datadog

$40.36

-0.33 (-0.81%)

, AMZN

Amazon.com

$1,752.70

15.21 (0.88%)

17:56
11/18/19
11/18
17:56
11/18/19
17:56
Hot Stocks
Datadog announces support for AWS CloudFormation Registry and CLI »

Datadog (DDOG) announced…

DDOG

Datadog

$40.36

-0.33 (-0.81%)

AMZN

Amazon.com

$1,752.70

15.21 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

17:55
11/18/19
11/18
17:55
11/18/19
17:55
Conference/Events
Morgan Stanley analyst to hold an analyst/industry conference call »

Managing Director &…

GVA

Granite Construction

$26.50

-0.6 (-2.21%)

17:54
11/18/19
11/18
17:54
11/18/19
17:54
Hot Stocks
Granite Construction awarded $14M airfield improvement project in California »

Granite announced it was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZS

Zscaler

$44.46

-1.37 (-2.99%)

, MSFT

Microsoft

$150.35

0.4 (0.27%)

17:51
11/18/19
11/18
17:51
11/18/19
17:51
Initiation
Zscaler, Microsoft initiated at DA Davidson »

Zscaler initiated with a…

ZS

Zscaler

$44.46

-1.37 (-2.99%)

MSFT

Microsoft

$150.35

0.4 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 04

    Dec

  • 09

    Dec

  • 16

    Dec

OKTA

Okta

$121.21

3.76 (3.20%)

17:51
11/18/19
11/18
17:51
11/18/19
17:51
Upgrade
Okta rating change at DA Davidson »

Okta pullback represents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 16

    Dec

PANW

Palo Alto Networks

$248.50

1.465 (0.59%)

17:48
11/18/19
11/18
17:48
11/18/19
17:48
Initiation
Palo Alto Networks initiated at DA Davidson »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Nov

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.